恆瑞醫藥(01276.HK)與印度Glenmark簽署協議 獲1800萬美元首付款及逾10億美元潛在里程碑款
格隆匯9月24日丨恆瑞醫藥(01276.HK)發佈公告,公司與GlenmarkSpecialty S.A.(以下簡稱“Glenmark Specialty”)達成協議,將公司具有自主知識產權的1類創新藥瑞康曲妥珠單抗(SHR-A1811)項目有償許可給GlenmarkSpecialty。瑞康曲妥珠單抗是恆瑞自主研發的以HER2爲靶點的抗體偶聯藥物(ADC),可通過與HER2表達的腫瘤細胞結合並內吞,在腫瘤細胞溶酶體內通過蛋白酶剪切釋放毒素,誘導細胞週期阻滯從而誘導腫瘤細胞凋亡。其釋放的毒素具有高透膜性,可發揮旁觀者殺傷效應,進一步提高抗腫瘤療效。
恆瑞將瑞康曲妥珠單抗在除中國大陸、中國香港、中國澳門及中國臺灣、美國、加拿大、歐洲、日本、俄羅斯、亞美尼亞、阿塞拜疆、白俄羅斯、哈薩克斯坦、吉爾吉斯斯坦、摩爾多瓦、塔吉克斯坦、土庫曼斯坦和烏茲別克斯坦外的全球範圍內開發及商業化的獨家權利有償許可給GlenmarkSpecialty。Glenmark Specialty將向恆瑞支付1800萬美元首付款。恆瑞有資格獲得與註冊和銷售相關的里程碑付款,最高可達10.93億美元。根據瑞康曲妥珠單抗在授權範圍內的銷售情況,Glenmark Specialty將向恆瑞支付相應的銷售提成。
Glenmark Specialty隸屬於Glenmark Pharmaceuticals公司,Glenmark Pharmaceuticals是一家以研究爲主導的全球製藥公司,總部位於印度孟買,於印度國家證券交易所(股份代碼:GLENMARK)以及孟買證券交易所(股份代碼:532296)上市,業務涵蓋創新藥、仿製藥及OTC領域,重點關注呼吸、皮膚及腫瘤學治療領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.